Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?
Some at patient-focused drug development meeting argue that cutting opioid use should not be considered treatment failure and that medications allowing controlled opioid use may be beneficial.
You may also be interested in...
Gottlieb Leaves FDA Feeling Good About Generic Approvals, But Concerned About Innovative Competition
In interview with the Pink Sheet, US FDA Commissioner Scott Gottlieb offers a final reflection of his time as commissioner.
A Pink Sheet analysis illustrates how the outgoing commissioner enhanced FDA's ability to facilitate the further development of innovative drugs.
The advisory committee will discuss a broad range of questions on a facet of FDA's opioid strategy that has received less attention than the others.